 |
 |
July - September 2011 |
|
|
Dear Damon Runyon Scientists,
October began with bittersweet news. We were thrilled to hear that Ralph M. Steinman, MD (Damon Runyon Clinical Investigator Mentor) of The Rockefeller University, New York, received the Nobel Prize in Physiology or Medicine for the discovery of dendritic cells, yet greatly saddened to hear that he had passed away of pancreatic cancer only days prior to the announcement.
On a happier note, we recently held our 11th annual Fellows’ Retreat. This year’s meeting, in San Jose, California, was a terrific gathering: the highest-quality science was presented, valuable networking took place, and new friendships and collaborations were developed.
Last week, we welcomed all of our Damon Runyon-Rachleff Innovators to New York City for the first Innovators’ Symposium. It was amazing to have all of them together and to hear about the progress each of them is making. In addition, the Innovation Award Committee met to review applications and select finalists for our fifth class of Innovators (to be announced in January). Our Fellowship Award Committee will meet in November to select a new class of Fellows and the recipients of the new Dale F. Frey Award for Breakthrough Scientists. Stay tuned for announcements of our newest awardees.
Please see below for the latest update on exciting news and findings from your fellow Damon Runyon scientists – current and former. These are just the publications and awards that we are aware of, so we apologize if we have not included your work. Lay summaries of some of this work are posted on the News page of our website, along with additional news about our Scientific Committee and Board members.
Thanks again to those of you who have sent us updates on your recent progress.
Please stay in touch, and enjoy the fall!
Best regards,
Yung S. Lie, PhD
Scientific Director
Damon Runyon Cancer Research Foundation
|
|
 |
AWARDS and HONORS |
 |
|
NIH High-Risk Research Award recipients:
Pioneer Award:
Brenda L. Bass, PhD (Fellow ‘85-‘88), University of Utah, Salt Lake City
William M. Clemons, PhD (Fellow ‘02-‘04), California Institute of Technology, Pasadena
Tao Pan, PhD (Fellow ‘91-‘93), University of Chicago
New Innovator Award:
Heather R. Christofk, PhD (Innovator ‘10-‘12), University of California, Los Angeles
Lea A. Goentoro, PhD (Fellow ‘07-‘10), California Institute of Technology, Pasadena
|
|
|
PUBLICATIONS |
|
Koichi Akashi, MD, PhD (Scholar ‘02-‘04), Kyushu University Graduate School of Medical Sciences, Japan
Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, Mori Y, Iino T, Yamauchi T, Eto T, Niiro H, Iwasaki H, Takenaka K, Akashi K. Cancer Cell. 2011 Aug 16;20(2):246-59.
Scott A. Armstrong, MD, PhD (Lilly Clinical Investigator ‘03-‘08) of Children’s Hospital Boston, Boston
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. Cancer Cell. 2011 Jul 12;20(1):66-78.
Differential niche and Wnt requirements during acute myeloid leukemia progression. Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA. Blood. 2011 Jul 15.
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Cancer Cell. 2011 Jul 12;20(1):53-65.
James E. Bradner, MD (Damon Runyon-Rachleff Innovator ‘11-‘13), Dana-Farber Cancer Institute, Boston
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc.
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. Cell. 2011 Sep 1.
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. Nature. 2011 Aug 3. doi: 10.1038/nature10334.
Marcia S. Brose, MD, PhD (Siemens Clinical Investigator ‘05-‘10), University of Pennsylvania, Philadelphia
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. BMC Cancer. 2011 Aug 11;11:349.
Ronald J. Buckanovich, MD, PhD (Clinical Investigator ‘08-‘11), University of Michigan, Ann Arbor
Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G. Cancer Biol Ther. 2011 Aug 1;12(3).
Joseph A. Califano, III, MD (Lilly Clinical Investigator ‘01-‘06), The Johns Hopkins’ Kimmel Cancer Center, Baltimore
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Science. 2011 Aug 26;333(6046):1154-7.
Leah E. Cowen, PhD (Fellow ‘03-‘05), University of Toronto, Toronto
Hsp90 governs dispersion and drug resistance of fungal biofilms. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. PLoS Pathog. 2011 Sep;7(9):e1002257.
Erik W. Debler, PhD (Fellow ‘08-‘10), The Rockefeller University, New York
Structural and functional analysis of an essential nucleoporin heterotrimer on the cytoplasmic face of the nuclear pore complex. Yoshida K, Seo HS, Debler EW, Blobel G, Hoelz A. Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16571-6.
The structure of the nuclear pore complex. Hoelz A, Debler EW, Blobel G. Annu Rev Biochem. 2011 Jun 7;80:613-43.
Charles G. Drake, MD, PhD (Lilly Clinical Investigator ‘04-‘09), The Johns Hopkins’ Kimmel Cancer Center, Baltimore
Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, Netto G, Pardoll DM, Drake CG. Prostate. 2011 Jul 14. doi: 10.1002/pros.21453.
Michael J. Emanuele, PhD (Fellow ‘08-‘11) Harvard Medical School and Brigham and Women’s Hospital, Boston
Global Identification of Modular Cullin-RING Ligase Substrates. Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, Guo A, Chen YN, Rush J, Hsu PW, Yen HC, Elledge SJ. Cell. 2011 Sep 28.
Rafael Fonseca, MD (Lilly Clinical Investigator ‘00-‘05), Mayo Clinic, Scottsdale
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Blood. 2011 Aug 22.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Blood. 2011 Sep 15;118(11):2970-5.
Mark B. Gerstein, PhD (Fellow ‘94-‘96), Yale University, New Haven
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch BL, Weiss SW, Debiec-Rychter M, Sciot R, West RB, Lazar AJ, Ashworth A, Reis-Filho JS, Lord CJ, Gerstein MB, Rubin MA, Rubin BP. Sci Transl Med. 2011 Aug 31;3(98):98ra82.
Maura L. Gillison, MD, PhD (Lilly Clinical Investigator ‘00-‘05), Ohio State University Comprehensive Cancer Center, Columbus
Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal “Pap-Test Equivalent” in High-Risk Populations. Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Cancer Prev Res (Phila). 2011 Sep;4(9):1378-84.
Nathanael S. Gray, PhD (Damon Runyon-Rachleff Innovator ‘08-‘10), Dana-Farber Cancer Institute, Boston
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Nat Med. 2011 Aug 7. doi: 10.1038/nm.2402.
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA. Cancer Res. 2011 Sep 15;71(18):6051-60.
Kristina M. Herbert, PhD (Fellow ‘09-‘11), Yale University, New Haven
A Compound That Inhibits the HOP-Hsp90 Complex Formation and Has Unique Killing Effects in Breast Cancer Cell Lines. Pimienta G, Herbert KM, Regan L. Mol Pharm. 2011 Oct 5.
John V. Heymach, MD, PhD (Lilly Clinical Investigator ‘04-‘09), The University of Texas MD Anderson Cancer Center, Houston
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Cancer Res. 2011 Aug 15;71(16):5512-21.
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Clin Cancer Res. 2011 Sep 1;17(17):5705-14.
Marshall Horwitz, MD, PhD (Fellow ‘94), University of Washington, Seattle
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D’Andrea RJ, Horwitz MS, Scott HS. Nat Genet. 2011 Sep 4;43(10):1012-7.
Rebecca A. Ihrie, PhD (Fellow ‘07-‘09), University of California, San Francisco
Corridors of migrating neurons in the human brain and their decline during infancy. Sanai N, Nguyen T, Ihrie RA, Mirzadeh Z, Tsai HH, Wong M, Gupta N, Berger MS, Huang E, Garcia-Verdugo JM, Rowitch DH, Alvarez-Buylla A. Nature. 2011 Sep 28. doi: 10.1038/nature10487.
Katrin Karbstein, PhD (Fellow ‘04-‘06), The Scripps Research Institute, Jupiter
and Georgios Skiniotis, PhD (Fellow ’04-’07), University of Michigan, Ann Arbor
Ribosome assembly factors prevent premature translation initiation by 40S assembly intermediates. Strunk BS, Loucks CR, Su M, Vashisth H, Cheng S, Schilling J, Brooks CL 3rd, Karbstein K, Skiniotis G. Science. 2011 Sep 9;333(6048):1449-53.
Mondira Kundu, MD, PhD (Fellow ‘00-‘03), St. Jude Children’s Research Hospital, Memphis
Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, Zhang J, Iyengar R, Jung CH, Suen DF, Steeves MA, Yang CY, Prater SM, Kim DH, Thompson CB, Youle RJ, Ney PA, Cleveland JL, Kundu M. Mol Cell. 2011 Aug 19;43(4):572-85.
Gabriel C. Lander, PhD (Merck Fellow ‘10-‘13), Lawrence Berkeley National Lab, Berkeley
Structures of the RNA-guided surveillance complex from a bacterial immune system. Wiedenheft B, Lander GC, Zhou K, Jore MM, Brouns SJ, van der Oost J, Doudna JA, Nogales E. Nature. 2011 Sep 21;477(7365):486-9. doi: 10.1038/nature10402.
Li Li, MD, PhD (Lilly Clinical Investigator ‘01-‘06), Case Western Reserve University, Cleveland
Ortiz, A. P., Thompson, C. L., Chak, A., Berger, N. A. and Li, L. Insulin resistance, central obesity, and risk of colorectal adenomas. Cancer (2011), doi: 10.1002/cncr.26454
Costas A. Lyssiotis, PhD (Fellow ‘10-‘13), Beth Israel Deaconess Medical Center, Boston
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG. Nat Genet. 2011 Jul 31;43(9):869-74.
Pierre P. Massion, MD (Lilly Clinical Investigator ‘03-‘08), Vanderbilt University, Nashville
Expression of focal adhesion kinase in small-cell lung carcinoma. Ocak S, Chen H, Callison C, Gonzalez AL, Massion PP. Cancer. 2011 Jul 28. doi: 10.1002/cncr.26382.
Patrick T. McGrath, PhD (Fellow ‘06-‘09), University of California, San Francisco
Parallel evolution of domesticated Caenorhabditis species targets pheromone receptor genes. McGrath PT, Xu Y, Ailion M, Garrison JL, Butcher RA, Bargmann CI. Nature. 2011 Aug 17;477(7364):321-5.
Matthew L. Meyerson, MD, PhD (Damon Runyon Fellow ‘95-‘98), Dana-Farber Cancer Institute, Boston
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence M, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio R, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. Science. 2011 Jul 28.
David Mu, PhD (Fellow ‘94-‘97), Pennsylvania State University College of Medicine, Hershey
miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D. Genes Dev. 2011 Aug 15;25(16):1734-45.
Peter S. Nelson, MD (Clinical Investigator Mentor, Scholar ‘02-‘04), Fred Hutchinson Cancer Research Center, Seattle
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Kumar A, White TA, Mackenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. Proc Natl Acad Sci U S A. 2011 Sep 26.
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG. Nat Biotechnol. 2011 Jun 19;29(7):625-34.
James M. Olson, MD, PhD (Lilly Clinical Investigator ‘02-‘07), Fred Hutchinson Cancer Research Center, Seattle
Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. J Clin Oncol. 2011 Sep 10;29(26):3529-34.
Elaine A. Ostrander, PhD (Fellow ’87-’90), Fred Hutchinson Cancer Research Center, Seattle
Genetic Variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality. Lin DW, Fitzgerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL. Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1928-36.
Jeremy N. Rich, MD (Lilly Clinical Investigator ‘04-‘09), Cleveland Clinic, Cleveland
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN. Cell. 2011 Jul 8;146(1):53-66.
John L. Rinn, PhD (Innovator ‘09-‘11, Fellow ‘05-‘07), Harvard University, Cambridge
lincRNAs act in the circuitry controlling pluripotency and differentiation. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, Lander ES. Nature. 2011 Aug 28;477(7364):295-300.
John L. Rinn, PhD (Innovator ‘09-‘11, Fellow ‘05-‘07), Harvard University, Cambridge
and Cole Trapnell, PhD (Fellow ‘11-‘14), Harvard University, Cambridge
Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Genes Dev. 2011 Sep 15;25(18):1915-27.
Julien Sage, PhD (Scholar ’05-’07), Stanford University Medical School, Stanford
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. J Exp Med. 2011 Sep 26;208(10):1963-76.
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Sci Transl Med. 2011 Aug 17;3(96):96ra77.
Ramesh A. Shivdasani, MD, PhD (Scholar ‘98-‘99), Dana-Farber Cancer Institute, Boston
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Sci Transl Med. 2011 Sep 7;3(99):99ra86.
Aaron F. Straight, PhD (Fellow ‘98-‘01, Scholar ‘05-‘07), Stanford University Medical School, Stanford
CENP-C recruits M18BP1 to centromeres to promote CENP-A chromatin assembly. Moree B, Meyer CB, Fuller CJ, Straight AF. J Cell Biol. 2011 Sep 19;194(6):855-71.
In vitro centromere and kinetochore assembly on defined chromatin templates. Guse A, Carroll CW, Moree B, Fuller CJ, Straight AF. Nature. 2011 Aug 28;477(7364):354-8.
Jesús Torres-Vazquez, PhD (Fellow ‘02-‘05), New York University, New York
Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres-Vázquez J. Dev Cell. 2011 Aug 16;21(2):301-14.
Monte M. Winslow, PhD (Fellow ‘06-‘09), Massachusetts Institute of Technology, Cambridge
Nuclear factor I/B is an oncogene in small cell lung cancer. Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. Genes Dev. 2011 Jul 15;25(14):1470-5.
John M. Timmerman, MD (Lilly Clinical Investigator ‘05-‘10), University of California, Los Angeles
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Clin Cancer Res. 2011 Jul 1;17(13):4232-44.
Jedd D. Wolchok, MD, PhD (Lilly Clinical Investigator ‘03-‘08), Memorial Sloan-Kettering Cancer Center, New York
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, Dematteo RP. Nat Med. 2011 Aug 28;17(9):1094-100.
Hai Yan, MD, PhD (Damon Runyon Scholar ‘05-‘07), Duke University, Durham
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW. Science. 2011 Sep 9;333(6048):1453-5.
» Visit the New Discoveries and Honors page for more
|
|
|
|
|
|
To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
